NASDAQ:ALLK Allakos (ALLK) Stock Price, News & Analysis $0.92 +0.05 (+5.78%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.87▼$0.9250-Day Range$0.69▼$1.4452-Week Range$0.68▼$5.64Volume207,618 shsAverage Volume981,042 shsMarket Capitalization$81.02 millionP/E RatioN/ADividend YieldN/APrice Target$1.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Allakos alerts: Email Address Allakos MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside82.1% Upside$1.67 Price TargetShort InterestHealthy3.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment1.09Based on 6 Articles This WeekInsider TradingSelling Shares$87,935 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.22) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.72 out of 5 starsMedical Sector60th out of 936 stocksPharmaceutical Preparations Industry18th out of 436 stocks 3.1 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageAllakos has only been the subject of 3 research reports in the past 90 days.Read more about Allakos' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.30% of the outstanding shares of Allakos have been sold short.Short Interest Ratio / Days to CoverAllakos has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Allakos has recently decreased by 38.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAllakos has received a 74.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Allakos is -0.86. Previous Next 3.4 News and Social Media Coverage News SentimentAllakos has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Allakos this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ALLK on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows2 people have added Allakos to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $87,935.00 in company stock.Percentage Held by Insiders16.12% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allakos' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($1.22) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allakos' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Allakos Stock (NASDAQ:ALLK)Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Read More ALLK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLK Stock News HeadlinesJuly 3, 2024 | insidertrades.comAllakos Inc. (NASDAQ:ALLK) CFO Sells $87,934.64 in StockJuly 23, 2024 | finance.yahoo.comCan Allakos (NASDAQ:ALLK) Afford To Invest In Growth?July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 21, 2024 | americanbankingnews.comAllakos (NASDAQ:ALLK) Given New $1.00 Price Target at Jefferies Financial GroupJuly 17, 2024 | americanbankingnews.comAllakos Inc. (NASDAQ:ALLK) Sees Significant Decrease in Short InterestJune 25, 2024 | globenewswire.comAllakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety ProfileMay 29, 2024 | finanznachrichten.deAllakos Inc.: Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaMay 28, 2024 | globenewswire.comAllakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous UrticariaJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 15, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)May 10, 2024 | finanznachrichten.deAllakos Inc.: Allakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 10, 2024 | finance.yahoo.comAllakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings PredictionsMay 10, 2024 | markets.businessinsider.comAllakos Buy Rating: Clinical Promise and Financial Stability Drive Positive OutlookMay 9, 2024 | investorplace.comALLK Stock Earnings: Allakos Meets EPS for Q1 2024May 9, 2024 | globenewswire.comAllakos Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 3, 2024 | finance.yahoo.comWith 55% ownership of the shares, Allakos Inc. (NASDAQ:ALLK) is heavily dominated by institutional ownersApril 24, 2024 | markets.businessinsider.comMarket Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical DevelopmentsApril 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroSee More Headlines Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees131Year FoundedN/APrice Target and Rating Average Stock Price Target$1.67 High Stock Price Target$3.00 Low Stock Price Target$1.00 Potential Upside/Downside+82.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-99.88% Return on Assets-73.06% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio4.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book0.47Miscellaneous Outstanding Shares88,540,000Free Float74,271,000Market Cap$81.02 million OptionableOptionable Beta0.88 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Robert Alexander Ph.D. (Age 54)CEO & Director Comp: $1.5MDr. Adam L. Tomasi Ph.D. (Age 54)President Comp: $1.15MMr. Baird Radford III (Age 54)Chief Financial Officer Comp: $731.35kMs. Mary Cromwell Ph.D.Chief Technical OfficerDr. Chin Lee M.D. (Age 54)M.P.H., Chief Medical Officer Mr. Alan ChangDirector of Medical Affairs & Data AnalyticsMore ExecutivesKey CompetitorsZentalis PharmaceuticalsNASDAQ:ZNTLAlimera SciencesNASDAQ:ALIMFoghorn TherapeuticsNASDAQ:FHTXNektar TherapeuticsNASDAQ:NKTRMersana TherapeuticsNASDAQ:MRSNView All CompetitorsInsiders & InstitutionsHarlan Baird RadfordSold 87,064 sharesTotal: $87,934.64 ($1.01/share)Opaleye Management Inc.Bought 2,435,000 shares on 5/29/2024Ownership: 2.750%Ikarian Capital LLCBought 695,619 shares on 5/17/2024Ownership: 1.053%BVF Inc. ILBought 8,000,000 shares on 5/16/2024Ownership: 18.695%Redmile Group LLCSold 219,371 shares on 5/16/2024Ownership: 3.898%View All Insider TransactionsView All Institutional Transactions ALLK Stock Analysis - Frequently Asked Questions How have ALLK shares performed this year? Allakos' stock was trading at $2.73 at the start of the year. Since then, ALLK shares have decreased by 66.5% and is now trading at $0.9151. View the best growth stocks for 2024 here. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.09. When did Allakos IPO? Allakos (ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager. Who are Allakos' major shareholders? Top institutional investors of Allakos include Concourse Financial Group Securities Inc.. Insiders that own company stock include Harlan Baird Radford and Steven P James. View institutional ownership trends. How do I buy shares of Allakos? Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE) and Eastman Chemical (EMN). This page (NASDAQ:ALLK) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
